Prolonged Suppression of Insulin Release by a Somatostatin Analog
- 1 July 1978
- journal article
- research article
- Published by The Endocrine Society in Endocrinology
- Vol. 103 (1) , 81-85
- https://doi.org/10.1210/endo-103-1-81
Abstract
A somatostatin analog, [D-Ala5,D-Trp8]-somatostatin, selectively inhibited insulin and GH [growth hormone] release in rats. The release of these hormones is inhibited by an analog dose of 5 .mu.g/kg in short term experiments (15 min from analog administration to blood sampling), while glucagon levels are not lowered by analog doses as high as 500 .mu.g/kg. The lowered insulin to glucagon ratio results in hyperglycemia. [D-Ala5,D-Trp8]Somatostatin is also long acting; a 1 mg/kg dose results in hypoinsulinemia for 2 h and hyperglycemia for 3 h.This publication has 4 references indexed in Scilit:
- Somatostatin: Analogs with Selected Biological ActivitiesScience, 1977
- Dissociation of somatostatin effects. Peptides inhibiting the release of growth hormone but not glucagon or insulin in ratsLife Sciences, 1976
- Fasting Hypoglycemia in AdultsNew England Journal of Medicine, 1976
- Immunoassay of insulin with insulin-antibody precipitateBiochemical Journal, 1963